Heroin overdose deaths Injury, Occupational Diseases, Poisoning Poisoning by narcotics and psychodysleptics [hallucinogens]
Conditions
Interventions
Amended as of 08/10/2010:
Participants randomised to the treatment arm of the study will be given a pack on release from prison containing a single-use, safety-covered and pre-loaded s
Sponsors
Medical Research Council (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females, 18-44 years old at randomisation date 2. Incarceration begun at least seven days before randomisation date 3. History of heroin use by injection 4. Likely release date within three months of randomisation date 5. Has not been randomised in N-ALIVE and then withdrawn consent prior to release from prison
Exclusion criteria
Exclusion criteria: 1. History of adverse reaction to naloxone 2. Non-resident in England, Wales or Scotland 3. Most recent index release date is within six months of randomisation date 4. Index release date is missing and participant was previously randomised in N-ALIVE in the past year 5. Participant withdraws consent prior to release 6. Participant dies prior to release 7. Exclusion from qualitative follow-up if randomised to 'No qualitative follow-up' 8. Exclusion from qualitative follow up if randomised to 'Qualitative follow-up' but participant does not consent to this part of the pilot
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Numbers of participating prisons and eligible prisoners 2. Number of participants contacted in qualitative follow-up 3. Questionnaire data concerning post-release heroin use, naloxone carriage and use, overdoses witnessed and experienced Added 08/10/2010: 4. Numbers of heroin overdose deaths among participants in both arms of the pilot study Qualitative data will be measured at either the first two or four weeks post-release, or up to one year after release in the case of questionnaires in Scotland. Data concerning rates of participation will be monitored throughout the study's two-year duration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Amended as of 08/10/2010: The following will be measured at 12 weeks post-release: numbers of non-fatal A&E admissions among participants in both arms of the pilot study Initial information at time of registration: The following will be measured at 12 weeks post-release: 1. Numbers of heroin overdose deaths among participants in both arms of the pilot study 2. Numbers of non-fatal A&E admissions among participants in both arms of the pilot study | — |
Countries
United Kingdom
Outcome results
None listed